Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 1/10/2025 | $85.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $75.00 | Outperform | Robert W. Baird |
20-F - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
D - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
Cantor Fitzgerald initiated coverage of Bright Minds Biosciences with a rating of Overweight
H.C. Wainwright initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $85.00
Robert W. Baird initiated coverage of Bright Minds Biosciences with a rating of Outperform and set a new price target of $75.00
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud to announce two upcoming presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The Company's presentation details are as follows: Title: Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company ("Shares") at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the "Offering"). The Company is pleased to announce that the Offering included participation from Cormorant Asset Management, RA Capital Management, Perceptive Advisors, Janus Henderson Investors, Vivo Capital, Acuta Capital Partners, Schonfeld Strategic Advisors, and other
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br